Diyabetik ve nondiyabetik hastalarda nöromuskuler bloğun geri döndürülmesinin karşılaştırılması
Yükleniyor...
Dosyalar
Tarih
2013
Yazarlar
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Düzce Üniversitesi
Erişim Hakkı
info:eu-repo/semantics/openAccess
Özet
ÖZET Amaç: Çalışmamızda diyabetes mellituslu (DM) hastalarda nöromuskuler blokajın (NMB) sugammadeks ile geri döndürülme özelliklerinin nondiyabetik hastalarla karşılaştırmalı olarak araştırılması amaçlanmıştır. Gereç ve Yöntem: Diyabetik (n=21) ve nondiyabetik (n=20) olmak 2 grup oluşturuldu. Tüm hastalara premedikasyon uygulandı. Hastalar operasyon salonuna alındıktan sonra Datex Ohmeda S/5 Avance anestezi cihazı ile monitorizasyon uygulandı; EKG (DII derivasyonu), periferik oksijen satürasyonu (SPO2), non-invazif kan basıncı (SKB, DKB, OKB), solunum sayısı (SS), soluk sonu karbondioksit basıncı (ETCO2), inspiratuar sevofluran konsantrasyonları takip edildi. Nöromuskuler monitorizasyon sağlandı. Anestezi indüksiyonu propofol 2 mg/kg, fentanil 1 mcg/kg ile uygulandı. Kirpik refleksi kaybından sonra supramaksimal uyarı tespit edildi ve rokuronyum 0,6 mg/kg uygulandı. Belirlenmiş olan supramaksimal uyarı ile TOF stimulasyonu uygulandı, TOF 2 olduğunda endotrakeal entübasyon gerçekleştirildi. Anestezi idamesi %50 O2 + %50 hava ve sevofluran 1 MAC ile sağlandı. TOF monitorizasyonu 5 dakika aralıklarla sürdürüldü ve kaydedildi. İntraoperatif dönemde TOF 2 yanıtı alındığında rokuronyum 0,15 mg/kg idame dozu uygulandı. T2i süresi entübasyon süresi olarak, T2d süresi klinik etki süresi olarak kaydedildi. Operasyon sonunda sugammadeks 2 mg/kg uygulandı. TOF oranı 0,9 düzeyine ulaşınca süresi kaydedilerek hastalar ekstübe edildi. Bulgular: Çalışmamızda entübasyon süreleri diyabetik grupta 183,14±96,49 saniye iken, nondiyabetik grupta 155,10±42,41 saniye olarak bulundu. Klinik etki süresi diyabetik grupta 2549,61±913,17 saniye iken, nondiyabetik grupta 2208,95±475,00 saniye olarak bulundu. TOF oranı 0,9'a ulaşma süresi diyabetik grupta 434,61±857,09 saniye iken nondiyabetik grupta 250,45±108,44 saniye olarak bulundu. Gruplar arasında entübasyon süresi, klinik etki süresi, TOF oranı 0,9'a ulaşma süreleri açısından istatistiksel olarak anlamlı fark bulunmadı. Sonuç: Sonuç olarak diyabetik hastalarda nöromuskuler blokajın geri döndürülmesinde ve derlenme döneminde yaşanabilecek problemler açısından sugammadeksin iyi bir alternatif olduğu düşünülmüştür. ANAHTAR KELİMELER: diyabetes mellitus, nöromuskuler blokaj, postoperatif rezidüel kürarizasyon, rokuronyum bromür, sugammadeks
ABSTRACT Aim: In our study we aimed to compare the time of antagonism and intensity of effect of sugammadex which is used for antagonism of rocuronium on diabetic and non-diabetic patients. Methods: Included patients were divided into 2 groups: diabetic (n=21) and non-diabetic (n=20). All patients were premedicated. After arrival in the operating room, all patients were monitorised with Datex Ohmeda S/5 Avance and ECG (DII derivation), SPO2, SBP, DBP, MBP, respiratory rate, ETCO2, and inspiratory sevoflurane concentrations were recorded. Neuromuscular monitoring system was used. Anesthesia was induced with propofol 2 mg/kg and fentanyl 1 mcg/kg. After the loss of eyelid reflex the neuromuscular monitoring system automatically identified supramaximal stimulating currents and after that rocuronium 0,6 mg/kg was given. TOF stimulation with the supramaximal current were applied and by recording of second TOF value (TOF2) the patient was intubated. Anesthesia was maintained with 50% O2 + 50% air and sevoflurane of 1 MAC. TOF stimulation was applied and recorded every 20 seconds. Intraoperatively by return T2 rocuronium 0,15 mg/kg was given. T2i time was recorded as intubation time and T2d time was recorded as clinical effect time. At the end of the operation sugammadex 2 mg/kg was given. When TOF rate reached 0,9 patients were extubated and the time was recorded. Results: In our study intubation time in diabetics were 183,14±96,49 seconds whereas 155,10±42,41 seconds in nondiabetics. The clinical effect time were 2549,61±913,17 seconds in diabetics and 2208,95±475,00 seconds in nondiabetics. The time of TOF rate reaching 0,9 were 434,61±857,09 seconds in diabetics and 250,45±108,44 seconds in nondiabetics. There were no statistical significant difference between the two groups in intubation time, clinical effect time and time of TOF rate reaching 0,9. Conclusion: In conclusion we thought that sugammadex was an effective alternative for diabetic patients by reversing the effects of neuromuscular blocking agents and reducing problems in recovery period..
ABSTRACT Aim: In our study we aimed to compare the time of antagonism and intensity of effect of sugammadex which is used for antagonism of rocuronium on diabetic and non-diabetic patients. Methods: Included patients were divided into 2 groups: diabetic (n=21) and non-diabetic (n=20). All patients were premedicated. After arrival in the operating room, all patients were monitorised with Datex Ohmeda S/5 Avance and ECG (DII derivation), SPO2, SBP, DBP, MBP, respiratory rate, ETCO2, and inspiratory sevoflurane concentrations were recorded. Neuromuscular monitoring system was used. Anesthesia was induced with propofol 2 mg/kg and fentanyl 1 mcg/kg. After the loss of eyelid reflex the neuromuscular monitoring system automatically identified supramaximal stimulating currents and after that rocuronium 0,6 mg/kg was given. TOF stimulation with the supramaximal current were applied and by recording of second TOF value (TOF2) the patient was intubated. Anesthesia was maintained with 50% O2 + 50% air and sevoflurane of 1 MAC. TOF stimulation was applied and recorded every 20 seconds. Intraoperatively by return T2 rocuronium 0,15 mg/kg was given. T2i time was recorded as intubation time and T2d time was recorded as clinical effect time. At the end of the operation sugammadex 2 mg/kg was given. When TOF rate reached 0,9 patients were extubated and the time was recorded. Results: In our study intubation time in diabetics were 183,14±96,49 seconds whereas 155,10±42,41 seconds in nondiabetics. The clinical effect time were 2549,61±913,17 seconds in diabetics and 2208,95±475,00 seconds in nondiabetics. The time of TOF rate reaching 0,9 were 434,61±857,09 seconds in diabetics and 250,45±108,44 seconds in nondiabetics. There were no statistical significant difference between the two groups in intubation time, clinical effect time and time of TOF rate reaching 0,9. Conclusion: In conclusion we thought that sugammadex was an effective alternative for diabetic patients by reversing the effects of neuromuscular blocking agents and reducing problems in recovery period..
Açıklama
YÖK Tez No: 365355
Anahtar Kelimeler
Anestezi ve Reanimasyon, Anesthesiology and Reanimation, Anestezi, Anesthesia, Diabetes mellitus, Diabetes mellitus, Nöromusküler blok ajanları, Neuromuscular blocking agents, Postoperatif dönem, Postoperative period, Rokuronyum, Rocuronium, Sugammadeks, Suggamadex, diabetes mellitus, neuromuscular blockade, postoperative residual curarisation, rocuronium bromure, sugammadex
